InteRNA Technologies BV, a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, has announced that it was awarded an Innovation Credit of €1.3 million from the Dutch government to support the development of miRNA-based therapeutics for the treatment of melanoma.
The funding is granted by Agentschap NL, an agency of the Dutch Ministry of Economic Affairs, Agriculture and Innovation. The Innovation Credit funds development projects that are innovative and have strong commercial potential.
“We are very pleased to receive this funding for our melanoma programme as it recognises the innovative character and commercial outlook of this project, a prerequisite to qualify for this facility,” said Roel Schaapveld, CEO of InteRNA Technologies. “It allows us to further strengthen the R&D team and speed up the development of our miRNA-based therapy to treat more advanced stages of this aggressive form of cancer for which there currently is no adequate treatment.”
The facility will become available upon achievement of specific milestones. The purpose of the Innovation Credit is to reduce the financial risk for entrepreneurs and, as such, repayment of the credit, contributing 35 per cent of the total project budget of €3.8 million, is subject to the commercial success of the project.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 